NCT04676360

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Jacob Soumerai, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma. * This research study involves the study drug belantamab mafodotin. * Belantamab mafodotin is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a drug. It works by using the antibody portion to enter into the lymphoma cells, and then releasing the drug portion to kill the lymphoma cells.

Detailed description

This is a multicenter phase 2 study of belantamab mafodotin on participants with plasmablastic lymphoma and ALK+ large B-cell lymphoma.The research study procedures include screening for eligibility, and study treatment, including evaluations and follow up visits. * This research study involves the study drug belantamab mafodotin. * Participants may receive the study treatment until progression or intolerance, and will be followed up to 2 years. * It is expected that about 25 people will take part in this research study. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved belantamab mafodotin as a treatment for any disease. This study drug is investigational, and it is not known whether participants will benefit from taking belantamab mafodotin.

Conditions

• Relapsed Plasmablastic Lymphoma
• Refractory Plasmablastic Lymphoma
• Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Belantamab Mafodotin	Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.

Timeline

• Start date: 2021-07-01
• Primary completion: 2023-11-27
• Completion: 2024-11-26
• First posted: 2020-12-21
• Last updated: 2026-03-13
• Results posted: 2026-03-13

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study